RenovoRx will host its second quarter 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. Eastern Time. Management plans to discuss growing revenues from commercial sales of its FDA-cleared RenovoCath drug-delivery device, including a record $563,000 in sales in the first quarter of 2026, and increased adoption at high-volume U.S. cancer centers. The company will also provide an update on the Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine delivered via RenovoCath in locally advanced pancreatic cancer, with full enrollment expected in the very near future and final data anticipated in mid-to-late 2027. Recent pipeline progress includes FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer and continued support for investigator-initiated trials in borderline resectable and metastatic pancreatic cancer.
RenovoRx IncRecord Q1 2026 sales of $563,000 and increased adoption at high-volume U.S. cancer centers indicate growing demand for RenovoCath.